Shorter Radiation Plus Immunotherapy for Recurrent Rectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal cancer that has come back in the pelvis but has not spread to other organs.
- You have not had chemotherapy for this cancer before.
- You have not had radiation treatment to the pelvis within the last 6 months.
- You are in good general health (able to do daily activities without help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
This Phase 2 trial tests whether giving targeted radiation and an immunotherapy drug together can control locally recurring rectal cancer in the pelvis. It may help shrink tumors and slow disease growth, especially after certain prior treatments.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy before surgery for high-risk rectal cancer. The goal is to see if this combination shrinks the tumor more effectively and improves outcomes.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a new combination of radiation and drugs for people with a type of rectal cancer that has not spread. The goal is to shrink the tumor before surgery, using a shorter course of radiation followed by several medicines.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
Hear when a new Locally Recurrent Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.